Tuesday, the U.S. District Court for the District of New Jersey ruled in favor of Merck, finding that the company has correctly calculated the Patent Term Extension period for its muscle relaxant reversal medicine Bridion (sugammadex).
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,